Bumetanide in heart failure in infancy

Area of Science:

• Pediatrics
• Cardiology
• Pharmacology

Background:

• Congenital heart disease (CHD) frequently leads to cardiac failure in infants.
• Diuretic therapy is essential for managing fluid overload in these patients.

Purpose of the Study:

• To evaluate the efficacy and safety of bumetanide in infants with CHD and cardiac failure.
• To assess bumetanide's effects in both acute and long-term treatment settings.

Main Methods:

• A study involving 12 male infants for acute (3-day) assessment and 13 infants for long-term (mean 10.5 weeks) evaluation.
• Administration of bumetanide at varying doses, starting from 0.015 mg/kg.
• Monitoring for diuretic effects (natriuresis, chloruresis) and adverse events.

Main Results:

• Even a suboptimal dose (0.015 mg/kg) in the acute phase induced significant natriuresis and chloruresis.
• Bumetanide proved effective as a long-term diuretic in doses ranging from 0.015 mg/kg every other day to 0.10 mg/kg daily.
• No adverse side effects were reported during either the acute or long-term treatment periods.

Conclusions:

• Bumetanide is a safe and effective diuretic for managing cardiac failure in infants with congenital heart disease.
• The drug demonstrates efficacy in both short-term and extended treatment durations.
• Further research may explore optimal dosing strategies for bumetanide in this pediatric population.